Iain B McInnes Selected Research

Fatigue

3/2024	Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
12/2023	Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
10/2022	The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
10/2022	The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
1/2022	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
6/2020	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial.
12/2018	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Iain B McInnes Research Topics

Disease

103	Psoriatic Arthritis 03/2024 - 03/2007
103	Rheumatoid Arthritis 02/2024 - 05/2002
62	Inflammation (Inflammations) 08/2023 - 05/2002
51	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2024 - 08/2004
51	Arthritis (Polyarthritis) 03/2024 - 12/2002
33	Necrosis 02/2024 - 01/2006
19	Infections 11/2023 - 02/2003
19	Experimental Arthritis 08/2023 - 12/2002
15	Pain (Aches) 03/2024 - 05/2013
14	Ankylosing Spondylitis 11/2023 - 01/2016
14	Autoimmune Diseases (Autoimmune Disease) 01/2023 - 02/2003
12	Synovitis 02/2024 - 05/2002
10	Rheumatic Diseases (Rheumatism) 01/2023 - 10/2006
9	Joint Diseases (Joint Disease) 02/2024 - 08/2008
9	Tendinopathy (Tendonitis) 01/2021 - 10/2010
8	COVID-19 01/2023 - 01/2020
7	Fatigue 03/2024 - 12/2018
7	Disease Progression 12/2023 - 12/2007
6	Atherosclerosis 06/2015 - 02/2008
5	Chronic Disease (Chronic Diseases) 03/2024 - 08/2011
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2024 - 01/2019
5	Axial Spondyloarthritis 12/2023 - 01/2019
5	Musculoskeletal Diseases (Musculoskeletal Disease) 01/2022 - 07/2017
5	Myocardial Infarction 01/2019 - 01/2010
5	Osteoarthritis 01/2018 - 11/2010
4	Neoplasms (Cancer) 05/2024 - 02/2003
4	Cytokine Release Syndrome 12/2023 - 01/2020
4	Herpes Zoster 02/2023 - 12/2018
4	Hypoxia (Hypoxemia) 01/2020 - 02/2012
3	Hypertension (High Blood Pressure) 03/2024 - 01/2019
3	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2023 - 01/2022

Drug/Important Bio-Agent (IBA)

66	CytokinesIBA 01/2024 - 07/2004
27	Antirheumatic Agents (DMARD)IBA 03/2024 - 06/2004
26	Interleukin-17 (Interleukin 17)IBA 03/2024 - 11/2007
24	secukinumabIBA 03/2024 - 02/2014
22	InterleukinsIBA 03/2024 - 08/2004
21	guselkumabIBA 03/2024 - 01/2020
18	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2019 - 05/2002
17	Monoclonal AntibodiesIBA 01/2022 - 11/2010
15	Janus Kinase InhibitorsIBA 01/2024 - 09/2013
14	Tumor Necrosis Factor InhibitorsIBA 03/2024 - 12/2002
14	AntigensIBA 02/2024 - 07/2004
14	Interleukin-23 (Interleukin 23)IBA 12/2023 - 04/2014
14	LipidsIBA 01/2022 - 05/2005
13	Methotrexate (Mexate)FDA LinkGeneric 03/2024 - 02/2007
13	Adalimumab (Humira)FDA Link 02/2024 - 07/2010
13	C-Reactive ProteinIBA 10/2022 - 08/2013
12	Biomarkers (Surrogate Marker)IBA 12/2023 - 03/2007
12	Interleukin-33IBA 01/2017 - 02/2008
11	tofacitinibIBA 12/2023 - 01/2014
11	golimumab FDA Link 01/2023 - 08/2012
11	CollagenIBA 01/2021 - 12/2002
11	Ustekinumab (CNTO 1275)FDA Link 11/2019 - 08/2013
11	Interleukin-18 (Interleukin 18)IBA 12/2018 - 01/2003
10	Abatacept (Orencia)FDA Link 02/2024 - 08/2010
10	Proteins (Proteins, Gene)FDA Link 02/2024 - 07/2004
10	Interleukin-12 (IL 12)IBA 01/2024 - 10/2004
10	ChemokinesIBA 01/2023 - 07/2008
10	AutoantibodiesIBA 01/2023 - 03/2010
9	bimekizumabIBA 03/2024 - 01/2019
8	upadacitinibIBA 01/2024 - 01/2020
8	tocilizumab (atlizumab)FDA Link 01/2023 - 04/2015
8	Interleukin-15 (Interleukin 15)IBA 01/2018 - 05/2002
7	AntibodiesIBA 02/2024 - 02/2008
7	Immunoglobulin G (IgG)IBA 01/2024 - 07/2004
7	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2023 - 09/2013
7	Interleukin-6 (Interleukin 6)IBA 01/2023 - 08/2003
6	ametantrone (HAQ)IBA 03/2024 - 06/2014
6	CholesterolIBA 03/2024 - 02/2003
6	Interleukin-1 (Interleukin 1)IBA 01/2022 - 10/2004
6	LigandsIBA 01/2022 - 04/2009
6	Peptides (Polypeptides)IBA 04/2021 - 01/2009
5	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2023 - 10/2011
5	Infliximab (Remicade)FDA Link 01/2023 - 09/2010
5	Etanercept (Enbrel)FDA Link 01/2023 - 01/2016
5	GlucocorticoidsIBA 01/2022 - 12/2018
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 02/2003
5	Collagen Type II (Type II Collagen)IBA 03/2016 - 01/2009
4	VaccinesIBA 05/2024 - 10/2021
4	Janus KinasesIBA 02/2023 - 01/2020
4	Anti-Citrullinated Protein AntibodiesIBA 01/2023 - 10/2013
4	Rituximab (Mabthera)FDA Link 01/2023 - 07/2016
4	baricitinibIBA 01/2023 - 12/2018
4	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2023 - 02/2007
4	OvalbuminIBA 01/2022 - 07/2004
4	AlarminsIBA 01/2019 - 05/2013
4	mavrilimumabIBA 01/2018 - 09/2013
4	Liver X ReceptorsIBA 06/2017 - 09/2009
4	MicroRNAs (MicroRNA)IBA 06/2017 - 03/2012
4	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2016 - 07/2010
4	Lipoproteins (Lipoprotein)IBA 10/2016 - 09/2013
3	Interleukin-23 Subunit p19IBA 03/2024 - 01/2020
3	Rheumatoid FactorIBA 02/2024 - 01/2009
3	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2024 - 03/2021
3	sarilumabIBA 12/2023 - 01/2020
3	omega-Chloroacetophenone (Mace)IBA 11/2023 - 01/2019

Therapy/Procedure

66	Therapeutics 05/2024 - 06/2004
7	Biological Therapy 10/2021 - 10/2006
3	Immunomodulation 02/2024 - 01/2020
3	Precision Medicine 12/2023 - 09/2019